Floatz logo

Ixabepilone

Childhood Germ Cell Tumor

National Institutes of Health Clinical Center (CC)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Childhood Germ Cell Tumor cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Masonic Cancer Center, University of Minnesota
Phase 2BBB
ETOPOSIDE
City of Hope Medical Center
Phase 3BB
Carboplatin
City of Hope Medical Center
Phase 3BB
Thiotepa
Masonic Cancer Center, University of Minnesota
Phase 2BB
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 21 →

Same molecule, other indications

Ixabepilone is also rated in:

breast carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
metastatic neoplasmDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →